Medical Radiology and Radiation Safety. 2019. Vol. 64. No. 2. P. 41–51

DOI: 10.12737/article_5ca5faca81d911.03586886

A.S. Samoylov1, Zh.Zh. Smirnova1, V.A. Klimanov1,2, V.V. Yakovlev3, L.I. Shulepova4, Yu.D. Udalov1

The Main Directions of Clinical Application of Modern Proton Therapy

1. A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ;
2. National Research Nuclear University MEPhI, Moscow, Russia;
3. S.M. Kirov Military Medical Academy, Saint-Petersburg, Russia;
4. Federal High-Tech Center for Medical Radiology of Federal Medical Biological Agency, Dimitrovgrad, Russia

A.S. Samoylov – Director General, Dr. Sci. Med., Prof. RAS;
Zh.Zh. Smirnova – Head of Medical Physics Laboratory;
V.A. Klimanov – Leading Researcher, Dr. Sci. (Phys-Math), Professor at NRNU MEPhI;
V.V. Yakovlev – Dr. Sci. Med., Prof.;
L.I. Shulepova – Director General;
Yu.D. Udalov – Deputy Director General, PhD Med.


This paper analyzes the current state of clinical application of proton radiation therapy (PRT) for the treatment of cancer. In particular, the indications for the use of PRT for the treatment of specific pathologies, the results and condition of randomized clinical studies of PRT compared to photon radiation therapy (PhRT) are considered, the cost of PRT is compared with the cost of PhRT. The focus is on discussing the results of PRT using in advanced countriesand Russia for the treatment of several common tumor sites. In the conclusion of the work, the ways of further improvement of radiobiology, dose delivering technology and dosimetric support of PRT are considered.

Key words: proton therapy, oncology, medical indications, clinical results, randomized clinical trials


  1. PTCOG. Particle TherapyCo-operativeGroupWebsite, September 2018.
  2. Durante M. Paganetti H. Nuclear physics in particle therapy: a review. Rep Prog Phys. 2016;79:096702.
  3. Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95:45-53.
  4. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol. 2012;103(1):8-11.
  5. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110:962-5.
  6. Seibel I, Cordini D, Rehak M, Hager A, Riechardt AI, Böker A, et al. Recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches and outcome. Amer J Ophthalmol. 2015;160(4):628-36. DOI: 10.1016/j.ajo.2015.06.017
  7. Damato B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol. 2004;32:639-47.
  8. Munzenrider JE, Verhey LJ, Gragoudas ES, et al. Conservative treatment ofuveal melanoma: local recurrence after proton beam therapy. Int J Radiat Oncol Biol Phys. 1989;17:493-8.
  9. Munzenrider JE, Gragoudas ES, Seddon JM, et al. Conservative treatment of uveal melanoma: probability of eye retention after proton treatment. Int J Radiat Oncol Biol Phys. 1988;15:553-8.
  10. Gragoudas ES, Marie Lane A. Uveal melanoma: proton beam irradiation. Ophthalmol Clin North Amer. 2005;18:111-8. ix.
  11. Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006;65:780-7.
  12. Courdi A, Caujolle JP, Grange JD, et al. Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys. 1999;45:5-11.
  13. Sakurai H, Ishikawa H and Okumura T: Proton beam therapy in Japan: Current and future status. Jpan J Clin Oncol. 2016;46:885-92.
  14. Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Moham­med K, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1027-38. DOI: 1010.1016/S1470-2045(1014)70268-70262. Epub 72014 Jun 70226. [PubMed: 24980873].
  15. Debus J, Hug EB, Liebsch NJ, O’Farrel D, Finkelstein D, Efird J, Munzenrider JE. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys. 1997; 39:967-75. PubMed: 9392533.
  16. Fagundes MA, Hug EB, Liebsch NJ, Daly W, Efird J, Munzenrider JE. Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys. 1995;33:579-84. PubMed: 7558946.
  17. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 2009;75:1111-8. DOI: 1110.1016/j.ijrobp.2008.1112.1055. Epub 2009 Apr 1120. [PubMed: 19386442].
  18. Grosshans DR, Zhu XR, Melancon A, Allen PK, Poenisch F, Palmer M, et al. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes. Int J Radiat Oncol Biol Phys. 2014; 90:540-6. DOI: 510.1016/j.ijrobp.2014.1007.1005. Epub 2014 Sep 1026. [PubMed: 25304948].
  19. Wenkel E, Thornton AF, Finkelstein D, Adams J, Lyons S, De La Monte S, et al. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 48:1363-70. [PubMed: 11121635].
  20. Vernimmen F, Harris JK, Wilson JA, Melvill R, Smit BJ, Slabbert JP. Stereotactic proton beam therapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2001 Jan 1;49 (1):99-105.
  21. Noel G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Haie-Meder C, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005; 44:700–708. [PubMed: 16227160].
  22. Wattson D, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90 (3):532–9. DOI: 10.1016/j.ijrobp.2014.06.068.
  23. Ronson B, Schulte RW, Han KP, Loredo LN, Slater JM, Slater JD. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64 (2):425-34. DOI: 10.1016/j.ijrobp.2005.07.978.
  24. Petit J, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin producing adenomas. J Clin Endocrinol Metab. 2008 Feb;93 (2):393–9. DOI: 10.1210/jc.2007-1220.
  25. Petit J, Biller BM, Coen JJ, Swearingen B, Ancukiewicz M, Bussiere M, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2007 Nov-Dec;13 (7):726–34. DOI: 10.4158/EP.13.7.726.
  26. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001 Nov;2(11):683-90. DOI: 10.1016/S1470-2045 (01)00558-7.
  27. Nichols A, Chan AW, Curry WT, Barker FG, Deschler DG, Lin DT. Esthesioneuroblastoma: the Massachusetts eye and ear infirmary and Massachusetts General Hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base. 2008;18(5):327-37. DOI: 10.1055/s-2008-1076098.
  28. Herr M, Sethi RK, Meier JC, Chambers KJ, Remenschneider A, Chan A, et al. Esthesioneuroblastoma: an update on the Massachusetts eye and ear infirmary and Massachusetts General Hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. J Neurol. Surg. B Skull Base. 2014;75 (1):58-64. DOI: 10.1055/s-0033-1356493.
  29. Ross J, Al-Shahi Salman R. Interventions for treating brain arteriovenous malformations in adults. Cochrane Database Syst Rev. 2010 Jul 7;7:CD003436.
  30. Hattangadi-Gluth JA, Chapman PH, Kim D, et al. Single-fraction proton beam stereotactic radiosurgery for cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):338-46.
  31. Johnstone PA, McMullen KP, Buchsbaum JC, Douglas JG, Helft P. Pediatric CSI: Are protons the only ethical approach? Int J Radiat Oncol Biol Phys. 2013;87:228-30.
  32. Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014;120:126-33.
  33. Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng Y, Kornguth D, et al. Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. Phys Med Biol. 2009;54:2259-75.
  34. Merchant TE, Kiehna EN, Li C, Shukla H, Sengupta S, Xiong X, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys. 2006;65:210-221.
  35. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002;54:824-9.
  36. Athar BS, Paganetti H. Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother Oncol. 2011;98:87-92.
  37. Lee CT, Bilton SD, Famiglietti RM, Riley BA, Mahajan A, Chang EL, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: How do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys. 2005;63:362-72.
  38. Yock T, Schneider R, Friedmann A, Adams J, Fullerton B, Tarbell N. Proton radiotherapy for orbital rhabdomyosarcoma: Clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys. 2005;63: 1161-8.
  39. Mu X, Björk-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol 2005;44:554-62.
  40. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, at al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol. 2007;25:43-9.
  41. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831-7.
  42. Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, et al. The clinical case for proton beam therapy. Radiat Oncol. 2012;7:174.
  43. Vernimmen, et al. Stereotactic proton beam therapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2001;49(1):99-105.
  44. Cotter SE, McBride SM, Yock TI. Proton radiotherapy for solid tumors of childhood. Technology Cancer Research Treatment. 2012;11(3):267-78.
  45. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65(1):1-7.
  46. Shipley WU, et al. Proton radiation as boost therapy for localized prostatic carcinoma. JAMA. 1979;241(18):19120-5.
  47. Slater J, Yonemoto LT, Rossi CJ Jr, Reyes-Molyneux NJ, Bush DA, Antoine JE, et al. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998 Sep 1;42 (2):299-304.
  48. Slater J, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59 (2):348-52. DOI: 10.1016/j.ijrobp.2003.10.011.
  49. Hayes, Inc. Hayes Directory. Proton beam therapy for prostate cancer. Lansdale, PA: Hayes, Inc.; June 2016. UpdatedMay 2017.
  50. Bryant C, Smith TL, Henderson RH, et al. Five-Year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422-34.
  51. Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602.
  52. Takagi M, Demizu Y, Terashima K, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017 Oct;6(10):2234-43.
  53. Mitsyn GV, Ol’shevskii AG, Syresin EM. Proton therapy today and tomorrow. Weekly «Dubna». 2008;32:11-6. Available at: (Russian).
  54. Agapov AV, Gaevsky VN, Kizhaev EV, et al. Experience of Proton Radiotherapy at the Joint Institute for Nuclear Research, Dubna. Medical Radiology and Radiation Safety. 2019;64(2):61-9. (Russian).
  56. S.Berezin Medical Institute, Proton Therapy Center
  57. Gulidov IA, Mardynski YuS, Balakin VE, et al. New opportunities for proton therapy in Russia. Problems of Oncology. 2016;62(5);570-2.
  58. Kaprin AD, Galkin VN, Zhavoronkov LP, et al. Synthesis of fundamental and applied research in the basis for ensuring a high level of scientific results and their introduction into medical practice. Radiation and Risk. 2017;26(2):26-40. (Russian).
  59. Medvedeva KE, Gulidov IA, Mardynsky YuS, et al. Proton therapy for re-irradiation of recurrent gliomas. Medical Radiology and Radiation Safety. 2019;64(2):70-4. (Russian).
  60. Klimanov VA, Zabelin MV, Galyautdinova ZhZh. Proton radiation therapy: current state and prospects. Medical physics 2017(3):89-121. (Russian).
  61. Zabelin MV, Klimanov VA, Galyautdinova ZhZh, et al. Proton Radiation Therapy: Clinical Application Opportunities and Research Prospects. Research’n Practical Medicine Journal. 2018;5(1):82-95.
  62. Klimanov VA, Samoylov AS, Udalov YuD, et al. Physics of Proton Therapy Treatment Planning. Medical Radiology and Radiation Safety. 2019;64(2):23-32.
  63. Lundkvist J, Ekman M, Ericsson SR, Jönsson B, GlimeliusB. Protontherapy of cancer: potential clinical advantagesandcost-effectiveness. Acta Oncol. 2005;44(8):850-61

For citation: Samoylov AS, Smirnova ZhZh, Klimanov VA, Yakovlev VV, Shulepova LI, Udalov YuD. The Main Directions of Clinical Application of Modern Proton Therapy. Medical Radiology and Radiation Safety. 2019;64(2):41-51. (Russian).

DOI: 10.12737/article_5ca5faca81d911.03586886

PDF (RUS) Full-text article (in Russian)